"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 2 | 4 |
| 1999 | 2 | 1 | 3 |
| 2001 | 4 | 0 | 4 |
| 2002 | 4 | 1 | 5 |
| 2003 | 2 | 0 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 4 | 0 | 4 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 1 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 4 | 0 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 5 | 1 | 6 |
| 2022 | 3 | 0 | 3 |
| 2023 | 9 | 0 | 9 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025 Feb 25; 9(4):696-703.
-
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 01; 110(1):92-102.
-
Application of flow cytometry immunophenotypic analysis for the diagnosis of mature B-cell lymphomas/leukemias. Hum Pathol. 2025 Feb; 156:105711.
-
High-grade B-cell lymphomas: Double hit and non-double hit. Hum Pathol. 2025 Feb; 156:105700.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2024 Sep 01; 10(9):1195-1203.
-
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
-
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
-
Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018-2022): A real-world, retrospective study. Cancer Med. 2024 May; 13(10):e7284.
-
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica. 2024 05 01; 109(5):1460-1468.